EP1476138B8 - Formulations a liberation modifiee d'au moins une forme de tramadol - Google Patents

Formulations a liberation modifiee d'au moins une forme de tramadol Download PDF

Info

Publication number: EP1476138B8
Authority: EP; European Patent Office
Prior art keywords: tramadol; release formulations; modified release; polyglycol; melting point
Prior art date: 2002-02-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

EP03743147A

Other languages

German (de)

English (en)

Other versions

EP1476138A2 (fr

EP1476138B1 (fr

EP1476138A4 (fr

Inventor

Pawan Seth

Paul J. Maes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Valeant International Bermuda

Original Assignee

Valeant International Barbados SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-21

Filing date

2003-02-21

Publication date

2012-03-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27765948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1476138(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-21 Application filed by Valeant International Barbados SRL filed Critical Valeant International Barbados SRL

2003-02-21 Priority to SI200332108T priority Critical patent/SI1476138T1/sl

2004-11-17 Publication of EP1476138A2 publication Critical patent/EP1476138A2/fr

2008-05-07 Publication of EP1476138A4 publication Critical patent/EP1476138A4/fr

2011-12-07 Publication of EP1476138B1 publication Critical patent/EP1476138B1/fr

2012-02-13 Priority to CY20121100144T priority patent/CY1112517T1/el

2012-03-07 Application granted granted Critical

2012-03-07 Publication of EP1476138B8 publication Critical patent/EP1476138B8/fr

2023-02-21 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Paints Or Removers (AREA)

EP03743147A 2002-02-21 2003-02-21 Formulations a liberation modifiee d'au moins une forme de tramadol Expired - Lifetime EP1476138B8 (fr)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
SI200332108T SI1476138T1 (sl)	2002-02-21	2003-02-21	Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
CY20121100144T CY1112517T1 (el)	2002-02-21	2012-02-13	Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US35785102P	2002-02-21	2002-02-21
US357851P		2002-02-21
PCT/US2003/004866 WO2003072025A2 (fr)	2002-02-21	2003-02-21	Formulations a liberation modifiee d'au moins une forme de tramadol

Publications (4)

Publication Number	Publication Date
EP1476138A2 EP1476138A2 (fr)	2004-11-17
EP1476138A4 EP1476138A4 (fr)	2008-05-07
EP1476138B1 EP1476138B1 (fr)	2011-12-07
EP1476138B8 true EP1476138B8 (fr)	2012-03-07

Family

ID=27765948

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP03743147A Expired - Lifetime EP1476138B8 (fr)	2002-02-21	2003-02-21	Formulations a liberation modifiee d'au moins une forme de tramadol
EP03743148.3A Expired - Lifetime EP1476139B1 (fr)	2002-02-21	2003-02-21	Formes posologiques à libération controlée

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP03743148.3A Expired - Lifetime EP1476139B1 (fr)	2002-02-21	2003-02-21	Formes posologiques à libération controlée

Country Status (15)

Country	Link
US (4)	US7780987B2 (fr)
EP (2)	EP1476138B8 (fr)
JP (3)	JP5069395B2 (fr)
AT (1)	ATE536173T1 (fr)
AU (2)	AU2003211146B2 (fr)
CA (2)	CA2476201C (fr)
CY (1)	CY1112517T1 (fr)
DK (1)	DK1476138T3 (fr)
ES (2)	ES2627842T3 (fr)
MX (2)	MXPA04008100A (fr)
NO (1)	NO20043913L (fr)
NZ (2)	NZ535456A (fr)
PT (1)	PT1476138E (fr)
SI (1)	SI1476138T1 (fr)
WO (2)	WO2003072025A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ260408A (en)	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
US8323692B2 (en)	2002-02-21	2012-12-04	Valeant International Bermuda	Controlled release dosage forms
AU2003211146B2 (en)	2002-02-21	2007-07-19	Valeant International (Barbados) Srl	Controlled release dosage forms
US8128957B1 (en) *	2002-02-21	2012-03-06	Valeant International (Barbados) Srl	Modified release compositions of at least one form of tramadol
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1905435A3 (fr) *	2003-03-11	2008-05-14	Euro-Celtique S.A.	Régime de dosage de titrage pour tramadol à libération contrôlée
US7413749B2 (en) *	2003-03-11	2008-08-19	Purdue Pharma L.P.	Titration dosing regimen for controlled release tramadol
SI1575565T1 (sl) *	2003-08-08	2010-04-30	Biovail Lab Int Srl	Tableta bupropion hidroklorida z modificiranim sproĹˇŽŤanjem
US7206632B2 (en) *	2003-10-02	2007-04-17	Medtronic, Inc.	Patient sensory response evaluation for neuromodulation efficacy rating
US20050074469A1 (en) *	2003-10-03	2005-04-07	Charles Signorino	Stable lipophilic emulsions for acrylic coating and method of making
US20060172006A1 (en) *	2003-10-10	2006-08-03	Vincent Lenaerts	Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084531A1 (en) *	2003-10-16	2005-04-21	Jatin Desai	Tablet with aqueous-based sustained release coating
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20080096979A1 (en) *	2004-11-08	2008-04-24	Rubicon Research Pvt. Ltd.	Aqueous Pharmaceutical Coating
US20060099262A1 (en) *	2004-11-08	2006-05-11	Biokey, Inc.	Methods and formulations for making controlled release oral dosage form
US20060099261A1 (en) *	2004-11-08	2006-05-11	Biokey, Inc.	Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) *	2004-11-08	2013-11-19	Biokey, Inc.	Methods and formulations for making pharmaceutical compositions containing bupropion
CA2578626C (fr)	2005-06-27	2011-07-19	Biovail Laboratories International S.R.L.	Formulations a liberation modifiee d'un sel de bupropion
AU2006269225B2 (en)	2005-07-07	2011-10-06	Farnam Companies, Inc.	Sustained release pharmaceutical compositions for highly water soluble drugs
US8778395B2 (en) *	2005-08-11	2014-07-15	Andrx Labs, Llc	Diltiazem controlled release formulation and method of manufacture
RU2008113439A (ru)	2005-09-09	2009-10-20	Лабофарм Инк. (CA)	Композиции с замедленным высвобождением лекарственного средства
US8022075B2 (en) *	2005-11-30	2011-09-20	Fujifilm Ri Pharma Co., Ltd.	Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
ES2279715B1 (es) *	2005-12-26	2008-06-01	Laboratorios Lesvi, S.L.	Formulacion oral de olanzapina.
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
US20070264335A1 (en) *	2006-05-09	2007-11-15	Sherman Bernard C	Modified release tablets comprising tramadol
CZ300698B6 (cs) *	2006-06-16	2009-07-22	Zentiva, A. S.	Tableta s obsahem metforminu
WO2008008801A2 (fr) *	2006-07-11	2008-01-17	Mcneil Nutritionals, Llc	Vitamine se présentant sous une forme galénique solide destinée à la voie orale et compositions minérales associées
US7674479B2 (en)	2006-07-25	2010-03-09	Intelgenx Corp.	Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) *	2006-07-25	2014-04-22	Intelgenx Corp.	Controlled-release pharmaceutical tablets
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
AR071375A1 (es) *	2008-04-22	2010-06-16	Solvay Pharm Gmbh	Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
CA2638240C (fr)	2008-08-29	2010-02-02	Alexander Macgregor	Methode de traitement des anomalies de la glycemie et des variations de la glycemie
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2395983B1 (fr)	2009-02-13	2020-04-08	Boehringer Ingelheim International GmbH	Composition pharmaceutique contenant un inhibiteur sglt2 en combinaison avec un inhibiteur dpp-iv et optioenellement un autre agent antidiabetique
EP3646859A1 (fr)	2009-11-27	2020-05-06	Boehringer Ingelheim International GmbH	Traitement de patients diabétiques génotypés avec des inhibiteurs de dpp-iv tels que la linagliptine
US10610528B2 (en)	2009-12-08	2020-04-07	Intelgenx Corp.	Solid oral film dosage forms and methods for making same
US20110136815A1 (en)	2009-12-08	2011-06-09	Horst Zerbe	Solid oral film dosage forms and methods for making same
WO2011090725A2 (fr) *	2009-12-29	2011-07-28	Impax Laboratories, Inc.	Formes posologiques orales solides à effet de gastrorétention, comportant un polymère hydrophile gonflable
AU2011249722B2 (en)	2010-05-05	2015-09-17	Boehringer Ingelheim International Gmbh	Combination therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
PH12014500137A1 (en)	2011-07-15	2017-08-18	Boehringer Ingelheim Int	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013171167A1 (fr)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
FI126168B (en)	2012-09-18	2016-07-29	Novaldmedical Ltd Oy	A method for coating pharmaceutical substrates
US9532946B2 (en)	2012-11-20	2017-01-03	Intervet Inc.	Manufacturing of semi-plastic pharmaceutical dosage units
AU2014306759B2 (en)	2013-08-12	2018-04-26	Pharmaceutical Manufacturing Research Services, Inc.	Extruded immediate release abuse deterrent pill
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
WO2015095391A1 (fr)	2013-12-17	2015-06-25	Pharmaceutical Manufacturing Research Services, Inc.	Comprimé extrudé anti-abus à libération prolongée
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
WO2016010771A1 (fr)	2014-07-17	2016-01-21	Pharmaceutical Manufacturing Research Services, Inc.	Forme posologique remplie de liquide anti-abus à libération immédiate
CA2964628A1 (fr)	2014-10-20	2016-04-28	Pharmaceutical Manufacturing Research Services, Inc.	Forme galenique anti-abus de remplissage de liquide a liberation prolongee
WO2017211979A1 (fr)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinaisons de linagliptine et de metformine
JP2018043198A (ja) *	2016-09-15	2018-03-22	トヨタ自動車株式会社	粉粒体混合機
CN115192533A (zh) *	2016-12-15	2022-10-18	斯派尔治疗有限公司	新型替比培南匹伏酯速释和调释口服剂型
CN111712235A (zh) *	2018-01-16	2020-09-25	应用材料公司	金属氧化物包封的药物组合物及其制备方法
DE102018001601A1 (de) *	2018-03-01	2019-09-05	Mann+Hummel Gmbh	Koaleszenzabscheider, insbesondere zur Verwendung in einem Kompressordruckluftsystem, Kompressordruckluftsystem sowie Verwendung eines Koaleszenzabscheiders
MX2022001975A (es) *	2019-08-16	2022-03-11	Applied Molecular Transport Inc	Composiciones, formulaciones y produccion y purificacion de interleucinas.
US12233169B2 (en)	2019-08-27	2025-02-25	Applied Materials, Inc.	Vapor phase coating technology for pharmaceutical abuse deterrent formulations
TWI870622B (zh)	2020-10-02	2025-01-21	美商應用材料股份有限公司	製備氧化矽塗佈藥品的低溫處理
EP4243783A1 (fr)	2020-11-11	2023-09-20	Spero Therapeutics, Inc.	Formulation de comprimé de tébipénème pivoxil à dosage élevé
EP4408402A4 (fr)	2021-09-30	2025-08-06	Applied Materials Inc	Revêtement d'oxyde de silicium à basse température pour applications pharmaceutiques

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3097144A (en) *	1960-10-14	1963-07-09	Upjohn Co	Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US4800087A (en) *	1986-11-24	1989-01-24	Mehta Atul M	Taste-masked pharmaceutical compositions
JPS63215620A (ja) *	1987-03-03	1988-09-08	Nippon Soda Co Ltd	徐放性製剤
GB8707416D0 (en) *	1987-03-27	1987-04-29	Wellcome Found	Pharmaceutical formulations
GB8724763D0 (en) *	1987-10-22	1987-11-25	Aps Research Ltd	Sustained-release formulations
JP2700662B2 (ja) *	1988-06-22	1998-01-21	大正製薬株式会社	被覆製剤
ATE79029T1 (de) *	1989-02-11	1992-08-15	Bayer Ag	Arzneimittel mit kontrollierter wirkstoffabgabe.
US5292522A (en) *	1989-06-20	1994-03-08	Rohm Gmbh	Aqueous film coating agent for solid medicaments
EP0524180B1 (fr)	1990-04-11	1995-04-26	The Upjohn Company	Masquage du gout de l'ibuprofene
US5288505A (en)	1991-06-26	1994-02-22	Galephar P.R., Inc., Ltd.	Extended release form of diltiazem
US5580578A (en) *	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5376384A (en) *	1992-12-23	1994-12-27	Kinaform Technology, Inc.	Delayed, sustained-release pharmaceutical preparation
NZ260408A (en) *	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
AU7966694A (en) *	1993-07-21	1996-05-02	University Of Kentucky Research Foundation, The	A multicompartment hard capsule with control release properties
US5458888A (en)	1994-03-02	1995-10-17	Andrx Pharmaceuticals, Inc.	Controlled release tablet formulation
US5733575A (en) *	1994-10-07	1998-03-31	Bpsi Holdings, Inc.	Enteric film coating compositions, method of coating therewith, and coated forms
US5871776A (en)	1995-01-31	1999-02-16	Mehta; Atul M.	Controlled-release nifedipine
DE19615812A1 (de)	1996-04-20	1997-10-23	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19630035A1 (de) *	1996-07-25	1998-01-29	Asta Medica Ag	Tramadol Multiple Unit Formulierungen
AU5310898A (en)	1996-12-20	1998-07-17	Dumex-Alpharma A/S	Release-controlled coated tablets
US5788987A (en)	1997-01-29	1998-08-04	Poli Industria Chimica Spa	Methods for treating early morning pathologies
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
ES2263211T3 (es) *	1997-07-02	2006-12-01	Euro-Celtique S.A.	Formulaciones de tramadol de liberacion sostenida estabilizada.
US6056977A (en) *	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
ES2216335T3 (es) *	1997-12-08	2004-10-16	Bristol-Myers Squibb Company	Nuevas sales de metformina y procedimiento.
US6022554A (en) *	1997-12-15	2000-02-08	American Home Products Corporation	Polymeric microporous film coated subcutaneous implant
US6245357B1 (en) *	1998-03-06	2001-06-12	Alza Corporation	Extended release dosage form
US6156342A (en)	1998-05-26	2000-12-05	Andex Pharmaceuticals, Inc.	Controlled release oral dosage form
DE19826517B4 (de)	1998-06-15	2006-03-23	Baxter Healthcare S.A.	Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
ES2206868T3 (es) *	1998-07-15	2004-05-16	Merck Sante	Comprimidos que comprenden una combinacion de metformin glibenclamida.
UA73092C2 (uk)	1998-07-17	2005-06-15	Брістол-Майерс Сквібб Компані	Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20030153607A1 (en)	1998-11-12	2003-08-14	Smithkline Beecham P.L.C.	Novel composition and use
DE19901686A1 (de) *	1999-01-18	2000-07-20	Gruenenthal Gmbh	Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
IN191482B (fr)	1999-03-19	2003-12-06	Ranbaxy Lab Ltd
US6183779B1 (en) *	1999-03-22	2001-02-06	Pharmascience Inc.	Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
IL148411A0 (en) *	1999-08-31	2002-09-12	Gruenenthal Chemie	Delayed-action form of administration containing tramadol saccharinate
DE19940740A1 (de) *	1999-08-31	2001-03-01	Gruenenthal Gmbh	Pharmazeutische Salze
WO2001045668A2 (fr)	1999-12-20	2001-06-28	Schering Corporation	Composition de dose orale a liberation prolongee
US6419956B1 (en)	1999-12-30	2002-07-16	Ancile Pharmaceuticals	Odor-masking coating for a pharmaceutical preparation
PT1251832E (pt)	2000-02-04	2007-01-31	Depomed Inc	Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6627223B2 (en) *	2000-02-11	2003-09-30	Eurand Pharmaceuticals Ltd.	Timed pulsatile drug delivery systems
US6676966B1 (en)	2000-05-09	2004-01-13	Intellipharmaceutics Corp.	Extended release metformin hydrochloride formulations
IN192159B (fr)	2000-05-15	2004-02-28	Ranbaxy Lab Ltd
US6620439B1 (en) *	2000-10-03	2003-09-16	Atul M. Mehta	Chrono delivery formulations and method of use thereof
US6866866B1 (en)	2000-11-03	2005-03-15	Andrx Labs, Llc	Controlled release metformin compositions
US6749867B2 (en)	2000-11-29	2004-06-15	Joseph R. Robinson	Delivery system for omeprazole and its salts
SE0100200D0 (sv)	2001-01-24	2001-01-24	Astrazeneca Ab	New film coating
ITMI20010220A1 (it)	2001-02-05	2002-08-05	Valpharma Sa	Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
EP1372614A4 (fr)	2001-03-16	2007-10-31	Andrx Pharmaceuticals Llc	Preparation de sulfonyluree a liberation controlee
US7858118B2 (en) *	2001-04-11	2010-12-28	Galephar Pharmaceutical Research, Inc.	Extended release composition containing Tramadol
JP5138856B2 (ja) *	2001-06-20	2013-02-06	武田薬品工業株式会社	錠剤の製造方法
EP1429745A2 (fr)	2001-09-28	2004-06-23	McNEIL-PPC, INC.	Forme pharmaceutique composite ayant une partie incrustee
US20040126428A1 (en)	2001-11-02	2004-07-01	Lyn Hughes	Pharmaceutical formulation including a resinate and an aversive agent
US6723348B2 (en)	2001-11-16	2004-04-20	Ethypharm	Orodispersible tablets containing fexofenadine
US20030118647A1 (en)	2001-12-04	2003-06-26	Pawan Seth	Extended release tablet of metformin
US6667054B2 (en)	2001-12-05	2003-12-23	Bernard Charles Sherman	Metformin hydrochloride tablets
TWI252111B (en)	2001-12-14	2006-04-01	Solvay Pharm Gmbh	Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
WO2003051340A1 (fr)	2001-12-19	2003-06-26	Astrazeneca Ab	Nouvelle pellicule
EP1474123A1 (fr)	2002-01-03	2004-11-10	LEK Pharmaceuticals D.D.	Formulation pharmaceutique a liberation controlee contenant de la venlafaxine
JP2003290319A (ja) *	2002-01-30	2003-10-14	Takeda Chem Ind Ltd	錠剤の製造装置
AU2003211146B2 (en) *	2002-02-21	2007-07-19	Valeant International (Barbados) Srl	Controlled release dosage forms
US20040005358A1 (en)	2002-04-23	2004-01-08	Slugg Peter H.	Modified-release vasopeptidase inhibitor formulation, combinations and method
US6902746B2 (en)	2002-07-03	2005-06-07	Yung Shin Pharmaceutical Industrial Co., Ltd.	Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
SE0202353D0 (sv)	2002-08-01	2002-08-01	Astrazeneca Ab	New film coating
US7429619B2 (en)	2002-08-02	2008-09-30	Mcneil Consumer Healthcare	Polyacrylic film forming compositions
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
US8216609B2 (en)	2002-08-05	2012-07-10	Torrent Pharmaceuticals Limited	Modified release composition of highly soluble drugs
US7018658B2 (en)	2002-11-14	2006-03-28	Synthon Bv	Pharmaceutical pellets comprising tamsulosin
DE10260919A1 (de)	2002-12-20	2004-07-01	Röhm GmbH & Co. KG	Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
US20040185097A1 (en)	2003-01-31	2004-09-23	Glenmark Pharmaceuticals Ltd.	Controlled release modifying complex and pharmaceutical compositions thereof
US20050048118A1 (en)	2003-07-25	2005-03-03	Joan Cucala Escoi	Modified release venlafaxine hydrochloride tablets
US20050025829A1 (en)	2003-07-29	2005-02-03	Kim Cherng-Ju	Controlled drug release tablets
US20050123596A1 (en)	2003-09-23	2005-06-09	Kohane Daniel S.	pH-triggered microparticles
EP1523981A1 (fr)	2003-10-13	2005-04-20	Wyeth	Préparations à libération prolongée de la venlafaxine
US20050084531A1 (en)	2003-10-16	2005-04-21	Jatin Desai	Tablet with aqueous-based sustained release coating
US7671094B2 (en) *	2005-06-27	2010-03-02	Biovail Laboratories International S.R.L.	Bupropion hydrobromide and therapeutic applications
CA2578626C (fr) *	2005-06-27	2011-07-19	Biovail Laboratories International S.R.L.	Formulations a liberation modifiee d'un sel de bupropion

2003
- 2003-02-21 AU AU2003211146A patent/AU2003211146B2/en not_active Expired
- 2003-02-21 AU AU2003211145A patent/AU2003211145B2/en not_active Ceased
- 2003-02-21 WO PCT/US2003/004866 patent/WO2003072025A2/fr not_active Ceased
- 2003-02-21 CA CA002476201A patent/CA2476201C/fr not_active Expired - Fee Related
- 2003-02-21 CA CA002476496A patent/CA2476496C/fr not_active Expired - Fee Related
- 2003-02-21 PT PT03743147T patent/PT1476138E/pt unknown
- 2003-02-21 JP JP2003570772A patent/JP5069395B2/ja not_active Expired - Fee Related
- 2003-02-21 SI SI200332108T patent/SI1476138T1/sl unknown
- 2003-02-21 NZ NZ535456A patent/NZ535456A/en not_active IP Right Cessation
- 2003-02-21 NZ NZ535455A patent/NZ535455A/en not_active IP Right Cessation
- 2003-02-21 US US10/370,109 patent/US7780987B2/en not_active Expired - Lifetime
- 2003-02-21 ES ES03743148.3T patent/ES2627842T3/es not_active Expired - Lifetime
- 2003-02-21 MX MXPA04008100A patent/MXPA04008100A/es active IP Right Grant
- 2003-02-21 EP EP03743147A patent/EP1476138B8/fr not_active Expired - Lifetime
- 2003-02-21 AT AT03743147T patent/ATE536173T1/de active
- 2003-02-21 MX MXPA04008164A patent/MXPA04008164A/es active IP Right Grant
- 2003-02-21 JP JP2003570835A patent/JP4704685B2/ja not_active Expired - Lifetime
- 2003-02-21 DK DK03743147.5T patent/DK1476138T3/da active
- 2003-02-21 WO PCT/US2003/004867 patent/WO2003072089A1/fr not_active Ceased
- 2003-02-21 ES ES03743147T patent/ES2377729T3/es not_active Expired - Lifetime
- 2003-02-21 EP EP03743148.3A patent/EP1476139B1/fr not_active Expired - Lifetime
2004
- 2004-09-20 NO NO20043913A patent/NO20043913L/no not_active Application Discontinuation
2008
- 2008-07-09 US US12/169,852 patent/US20080274177A1/en not_active Abandoned
2010
- 2010-04-05 JP JP2010086646A patent/JP2010155864A/ja active Pending
2012
- 2012-02-13 CY CY20121100144T patent/CY1112517T1/el unknown
2013
- 2013-05-13 US US13/892,657 patent/US20130245154A1/en not_active Abandoned
2014
- 2014-04-25 US US14/262,622 patent/US20150030675A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003211146B2 (en)	2007-07-19
NO20043913L (no)	2004-11-16
CA2476201A1 (fr)	2003-09-04
JP4704685B2 (ja)	2011-06-15
MXPA04008164A (es)	2005-05-17
US20080274177A1 (en)	2008-11-06
US7780987B2 (en)	2010-08-24
DK1476138T3 (da)	2012-02-20
WO2003072089A1 (fr)	2003-09-04
AU2003211145B2 (en)	2007-07-12
PT1476138E (pt)	2012-02-14
EP1476139A1 (fr)	2004-11-17
JP2005526047A (ja)	2005-09-02
EP1476138A2 (fr)	2004-11-17
EP1476139B1 (fr)	2017-05-17
US20130245154A1 (en)	2013-09-19
AU2003211146A1 (en)	2003-09-09
CA2476496C (fr)	2009-12-15
ES2377729T3 (es)	2012-03-30
SI1476138T1 (sl)	2012-07-31
US20040037883A1 (en)	2004-02-26
EP1476138B1 (fr)	2011-12-07
NZ535456A (en)	2006-08-31
EP1476138A4 (fr)	2008-05-07
JP2010155864A (ja)	2010-07-15
WO2003072025A2 (fr)	2003-09-04
AU2003211145A1 (en)	2003-09-09
JP5069395B2 (ja)	2012-11-07
WO2003072025A3 (fr)	2003-11-06
ES2627842T3 (es)	2017-07-31
JP2005526043A (ja)	2005-09-02
ATE536173T1 (de)	2011-12-15
EP1476139A4 (fr)	2007-12-26
CA2476201C (fr)	2009-09-01
MXPA04008100A (es)	2005-06-17
CA2476496A1 (fr)	2003-09-04
US20150030675A1 (en)	2015-01-29
NZ535455A (en)	2009-08-28
CY1112517T1 (el)	2015-12-09

Publication	Publication Date	Title
EP1476138B8 (fr)	2012-03-07	Formulations a liberation modifiee d'au moins une forme de tramadol
BG106030A (en)	2002-05-31	Pharmaceutical composition
CA2346001A1 (fr)	2000-04-06	Liberation regulee de compositions nanoparticulaires
PT1412384E (pt)	2008-03-28	Formulação estável de glp-1 modificado
CA2385890A1 (fr)	2001-04-05	Compositions a liberation regulee contenant de la nimesulide
CA2329005A1 (fr)	1999-10-28	Compositions pharmaceutiques contenant de l'acide folique, procedes et systemes d'administration correspondants
AU2001236457A1 (en)	2001-07-24	Compounds and compositions for delivering active agents
AU2845599A (en)	1999-09-20	Pharmaceutical compositions and their use
AU2003229084A1 (en)	2003-12-02	Methods and formulations for the delivery of pharmacologically active agents
WO2007048219A3 (fr)	2007-07-19	Composition medicamenteuse a liberation prolongee
AU2001284985A1 (en)	2002-03-04	Compounds and compositions for delivering active agents
IL150895A0 (en)	2003-02-12	Oral, nasal and pulmonary formulations of copolymer-1
BRPI0309651A2 (pt)	2016-11-29	método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida
CA2347195A1 (fr)	2000-04-27	Compositions pharmaceutiques orales contenant buprenorphine
AU2001288277A1 (en)	2002-03-04	Compounds and compositions for delivering active agents
AU2001227030A1 (en)	2002-06-03	Pharmaceutical composition for controlled release of an active ingredient
WO2001078682A3 (fr)	2002-04-18	Compositions pharmaceutiques a liberation prolongee
AU2003253968A1 (en)	2004-02-09	Aerosolized ceramic porcelains and glaze composition
AU2002316200A1 (en)	2002-12-23	Compound and composition for delivering active agents
MXPA04003540A (es)	2004-07-22	Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
WO2005009407A3 (fr)	2006-03-02	Formulations pharmaceutiques d'olanzapine administrees par voie orale
AU5211901A (en)	2001-08-07	Pharmaceutical compositions
AU1556000A (en)	2001-06-04	Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
WO2000007580A3 (fr)	2000-05-18	Compositions pharmaceutiques de lutte contre les maladies auto-immunes
WO2005062722A3 (fr)	2005-09-22	Composition pharmaceutique orale

Legal Events

Date	Code	Title	Description
2004-10-01	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-11-17	17P	Request for examination filed	Effective date: 20040820
2004-11-17	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
2004-11-17	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO
2005-11-02	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: BIOVAIL LABORATORIES INTERNATIONAL SRL
2008-05-07	A4	Supplementary search report drawn up and despatched	Effective date: 20080409
2008-09-24	17Q	First examination report despatched	Effective date: 20080821
2011-06-17	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2011-11-03	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2011-11-04	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2011-12-07	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
2011-12-07	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2011-12-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2011-12-21	RAP2	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL
2012-01-04	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2012-02-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 60339333 Country of ref document: DE Effective date: 20120202
2012-02-14	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20120206
2012-02-15	REG	Reference to a national code	Ref country code: NL Ref legal event code: T3
2012-02-20	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3
2012-02-28	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2012-02-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG Ref country code: CH Ref legal event code: PFA Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL Free format text: VALEANT INTERNATIONAL (BARBADOS) SRL#WELCHES, CHURCH STREET#CHRIST CHURCH 17154 (BB) -TRANSFER TO- VALEANT INTERNATIONAL (BARBADOS) SRL#WELCHES CHRIST CHURCH#BARBADOS BB 17154 (BB)
2012-03-07	RAP2	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL
2012-03-14	RAP2	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL
2012-03-30	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2377729 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120330
2012-04-16	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E006232 Country of ref document: EE Effective date: 20120215
2012-05-29	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E012805 Country of ref document: HU Ref country code: GR Ref legal event code: EP Ref document number: 20120400506 Country of ref document: GR Effective date: 20120417
2012-08-06	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 11701 Country of ref document: SK
2012-10-12	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2012-10-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2012-11-14	26N	No opposition filed	Effective date: 20120910
2013-01-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 60339333 Country of ref document: DE Effective date: 20120910
2013-07-03	REG	Reference to a national code	Ref country code: NL Ref legal event code: TD Effective date: 20130624
2013-08-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20130730 Year of fee payment: 11
2013-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SK Payment date: 20130719 Year of fee payment: 11 Ref country code: HU Payment date: 20130729 Year of fee payment: 11 Ref country code: DK Payment date: 20130725 Year of fee payment: 11 Ref country code: MC Payment date: 20130830 Year of fee payment: 11 Ref country code: EE Payment date: 20130729 Year of fee payment: 11 Ref country code: DE Payment date: 20130729 Year of fee payment: 11 Ref country code: NL Payment date: 20130726 Year of fee payment: 11 Ref country code: IE Payment date: 20130725 Year of fee payment: 11 Ref country code: FI Payment date: 20130729 Year of fee payment: 11 Ref country code: BG Payment date: 20130726 Year of fee payment: 11 Ref country code: CH Payment date: 20130729 Year of fee payment: 11 Ref country code: PT Payment date: 20130221 Year of fee payment: 11 Ref country code: AT Payment date: 20130719 Year of fee payment: 11 Ref country code: SI Payment date: 20130722 Year of fee payment: 11 Ref country code: SE Payment date: 20130729 Year of fee payment: 11 Ref country code: ES Payment date: 20130726 Year of fee payment: 11 Ref country code: CZ Payment date: 20130722 Year of fee payment: 11 Ref country code: GR Payment date: 20130729 Year of fee payment: 11
2013-11-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20130828 Year of fee payment: 11 Ref country code: TR Payment date: 20130723 Year of fee payment: 11 Ref country code: FR Payment date: 20130717 Year of fee payment: 11
2013-12-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20130726 Year of fee payment: 11
2014-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20130830 Year of fee payment: 11 Ref country code: CY Payment date: 20130723 Year of fee payment: 11
2014-08-29	REG	Reference to a national code	Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20140821
2014-08-31	BERE	Be: lapsed	Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL Effective date: 20140228
2014-09-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 60339333 Country of ref document: DE
2014-09-17	REG	Reference to a national code	Ref country code: NL Ref legal event code: V1 Effective date: 20140901
2014-09-29	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP Effective date: 20140228
2014-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140228 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221
2014-09-30	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG Ref country code: CH Ref legal event code: PL
2014-10-15	REG	Reference to a national code	Ref country code: EE Ref legal event code: MM4A Ref document number: E006232 Country of ref document: EE Effective date: 20140228 Ref country code: AT Ref legal event code: MM01 Ref document number: 536173 Country of ref document: AT Kind code of ref document: T Effective date: 20140221
2014-10-23	REG	Reference to a national code	Ref country code: GR Ref legal event code: ML Ref document number: 20120400506 Country of ref document: GR Effective date: 20140903
2014-10-29	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20140221
2014-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140930 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140903 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140228 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140228 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140228 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140901 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221
2014-11-04	REG	Reference to a national code	Ref country code: SK Ref legal event code: MM4A Ref document number: E 11701 Country of ref document: SK Effective date: 20140221
2014-11-21	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20141031
2014-11-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 60339333 Country of ref document: DE Effective date: 20140902
2014-11-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140222 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140222 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221 Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140222
2014-11-28	REG	Reference to a national code	Ref country code: SI Ref legal event code: KO00 Effective date: 20141007
2014-12-03	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2014-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140821
2015-01-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140228 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140902 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140228 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140228
2015-05-04	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20150504
2015-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140222
2016-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140221